Management of Obstructive Prosthetic Heart Valve Thrombosis: Thrombolytic Therapy or Anticoagulation?

Comment

Ahmet Güner et al. Can J Cardiol. 2021 Jun.

. 2021 Jun;37(6):938.e7.

doi: 10.1016/j.cjca.2021.01.026. Epub 2021 Feb 10.

No abstract available

Comment in

Reply to Güner et al.-Management of Obstructive Heart Valve Thrombosis: Differences Between Biological and Mechanical Prostheses.
Llopis Gisbert G, Vidal Urrutia V, Moruno Benita MA, Payá Chaume A, Berenguer Jofresa A, Cubillos Arango AM, Pérez Boscá JL, Payá Serrano R. Llopis Gisbert G, et al. Can J Cardiol. 2021 Jun;37(6):938.e9. doi: 10.1016/j.cjca.2021.02.011. Epub 2021 Feb 24. Can J Cardiol. 2021. PMID: 33636249 No abstract available.

Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19.
Llopis Gisbert G, Vidal Urrutia V, Moruno Benita MA, Payá Chaume A, Berenguer Jofresa A, Cubillos Arango AM, Pérez Boscá JL, Payá Serrano R. Llopis Gisbert G, et al. Can J Cardiol. 2021 Jun;37(6):938.e3-938.e6. doi: 10.1016/j.cjca.2020.10.008. Epub 2020 Oct 24. Can J Cardiol. 2021. PMID: 33485934 Free PMC article.

1. Llopis Gisbert G., Urrutia V.V., Moruno Benita M.A. Bioprosthetic valve thrombosis and obstruction secondary to COVID-19. Can J Cardiol. 2021;37:938.e3–938.e6. - PMC - PubMed
1. Özkan M., Gündüz S., Biteker M. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. JACC Cardiovasc Imaging. 2013;6:206–216. - PubMed
1. Otto C.M., Nishimura R.A., Bonow R.O. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35–e61. - PubMed
1. Bayam E., Kalçık M., Gürbüz A.S. The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis. Thromb Res. 2018;171:103–110. - PubMed